6533b7ddfe1ef96bd12753e0
RESEARCH PRODUCT
The Tick Salivary Protein Sialostatin L Inhibits the Th9-Derived Production of the Asthma-Promoting Cytokine IL-9 and Is Effective in the Prevention of Experimental Asthma
Edgar SchmittMarkus HoffmannMichalis KotsyfakisJohn F. AndersenMichael StassenValérie StaudtHelena HorkaSebastian ReuterNina DehzadBastian GerlitzkiTobias BoppJan KopeckyMatthias KleinChristian TaubeHansjörg Schildsubject
MaleSalivaIxodidaemedicine.medical_treatmentImmunologyEnzyme-Linked Immunosorbent AssayCell SeparationBiologyReal-Time Polymerase Chain ReactionArticleNeutralizationMiceImmune systemT-Lymphocyte SubsetsmedicineAnimalsImmunology and AllergyEosinophiliaAsthmaMice KnockoutMice Inbred BALB CReverse Transcriptase Polymerase Chain ReactionInterleukin-9Flow Cytometrymedicine.diseaseCystatinsCysteine proteaseAsthmarespiratory tract diseasesDisease Models AnimalCytokineIxodes scapularisImmunologyCytokinesFemalemedicine.symptomdescription
Abstract Ticks developed a multitude of different immune evasion strategies to obtain a blood meal. Sialostatin L is an immunosuppressive cysteine protease inhibitor present in the saliva of the hard tick Ixodes scapularis. In this study, we demonstrate that sialostatin L strongly inhibits the production of IL-9 by Th9 cells. Because we could show recently that Th9-derived IL-9 is essentially involved in the induction of asthma symptoms, sialostatin L was used for the treatment of experimental asthma. Application of sialostatin L in a model of experimental asthma almost completely abrogated airway hyperresponsiveness and eosinophilia. Our data suggest that sialostatin L can prevent experimental asthma, most likely by inhibiting the IL-9 production of Th9 cells. Thus, alternative to IL-9 neutralization sialostatin L provides the basis for the development of innovative therapeutic strategies to treat asthma.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2012-03-15 |